Iterum Therapeutics plc ITRM

Healthcare Biotechnology

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

NDAQ:ITRM - Post by User

Iterum Therapeutics plc > Iterum Therapeutics to Host Morning Conference Call on U.S.

<< Previous

Bullboard Posts

Comment by Ltcguy2001on Oct 28, 2024 8:02pm

26 Views

Post# 36286000

RE:Iterum Therapeutics to Host Morning Conference Call on U.S.

I was lucky to take a small 5,000 share position last Thursday @$1.20 and sold Friday at $2.18. Took my $6k back off the table but bought 3,500 @$1.40 with left over. Free and clear long hold. Might do it again if the market lets me.

<< Previous

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features